Platelet Count/Spleen Diameter Ratio and AST/ALT Ratio as Non-invasive Parameters for the Detection of Esophageal Varices in Patients with Cirrhosis

Authors
Suresh Raghavan¹, Arathi N²
Department of Medicine, Government TD Medical College, Alappuzha 688005
Correspondence Author
Suresh Raghavan
Professor of Medicine, Department of Medicine, Government Medical College, Alappuzha
Mobile: 9847155537. Email: arathi.n.iyer@gmail.com

ABSTRACT
Esophageal varices in liver cirrhosis is a major complication increasing its morbidity and mortality. Prevalence of esophageal varices in liver cirrhosis range from 60-80 %. Patients with cirrhosis should be screened for varices with esophageal endoscopy. Endoscopy is an invasive procedure and also may not be affordable for ordinary people in developing countries. This study aims to find out diagnostic efficacy of non invasive marker for detecting esophageal varices.

Materials and Methods: It is a Diagnostic test evaluation study of 1 year duration conducted in 140 cirrhotic patients admitted on Medicine and Gastroenterology ward in a tertiary care centre. Data collected and analysed using SPSS. ROC curve was drawn with different cut offs for Platelet count/Spleen thickness and AST/ALT ratio.

Result: PLC/ BPD ratio have sensitivity 74 % and specificity 88% which is statistically significant with a p value <.001. This ratio have a cut off value 919 with area under ROC curve 0.908 which denotes a good test. AST/ALT ratio have sensitivity 74% specificity 82 % which is statistically significant with a p value < .001 and the ratio have a cut off value 1.30 with area under ROC curve 0.794

Conclusion: Platelet count/spleen diameter ratio and AST/ALT ratio may be used as non invasive marker for esophageal varices in cirrhotic patients

Keywords: Esophageal varices, Endoscopy, Cirrhosis, Platelet count, spleen diameter, AST, ALT.

INTRODUCTION
Liver Cirrhosis contributes significantly to global health burden. Liver Cirrhosis is a major cause for morbidity and mortality in underdeveloped countries, owing to unawareness, inadequate facilities and financial implication related to the disease. The latest WHO data published in May 2014 indicate that liver disease deaths in India accounts for 2.44% of total deaths. Portal hypertension and esophageal varices (EVs) are common major complications of liver cirrhosis, occurring in approximately 24% to 80% of cases, with an extremely high mortality rate[1-3]. Others are ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, portal hypertensive gastropathy, infection, hepato renal syndrome, hepatocellular carcinoma.
The prevalence of esophageal varices in patients with liver cirrhosis may range from 60% to 80%, and the reported mortality from variceal bleeding ranges from 17% to 57% [4-7]. Therefore, the prevention of variceal bleeding is an important goal in management of patients with liver cirrhosis. The 1996 the American Association for the Study of Liver Disease (AASLD) single topic symposium recommended that cirrhotic patients should be screened for the presence of EV when portal hypertension is diagnosed [8]. Similarly, the Baveno III Consensus Conference on portal hypertension recommended that all cirrhotic patients should be screened for the presence of EV when liver cirrhosis is diagnosed [9]. Other groups suggest follow up endoscopy at 2–3 year intervals in patients without varices and at 1–2 year intervals in patients with small varices so as to evaluate the development or progression of this feature [10].

Primary prophylaxis with universal endoscopic screening of for EVs is recommended in conjunction with in patients who are at high-risk of variceal bleeding [11,12]. This screening is invasive, and many patients may not have varices, rendering this method cost-ineffective. Thus, noninvasive diagnosis of portal hypertension may be useful [2]. Recently, several studies have attempted to identify the variables that can noninvasively predict the presence of EVs (including large ones), examining various biochemical, clinical, and ultrasonographic parameters alone or in combination, with promising results [13-16]. Overall, the most common result of these studies was that parameters directly or indirectly linked to portal hypertension, such as splenomegaly and decreased platelet count, were predictors of the presence of EV. On the other hand, the presence of splenomegaly in cirrhotic patients is likely the result of vascular disturbances that are mainly related to portal hypertension [17] and the decrease in platelet count which most likely depends on hypersplenism caused by portal hypertension.

Most such variables, however, have several limitations, which has hindered the wide application of these results. Early studies were retrospective and were performed in a specific subgroup of patients—eg. patients on a wait list for liver transplantation [15,18-22]. In patients with chronic liver disease, thrombocytopenia is due primarily to portal Hypertension [23], thrombocytopenia can depend on other factors, such as shortened mean platelet lifetime, decreased thrombopoetin production, and the myelotoxic effects of alcohol or hepatitis viruses [24].

Moreover, in previous studies, there has been a lack in uniformity in the classification and diagnosis of EVs [15,18-22], in which EVs were not categorized by a single endoscopist or in the same endoscopy unit. Moreover, their focus on patients with large EVs might have led to the omission of an important subset of patients with less severe disease who required medical counseling. Thus, the analysis of the presence or absence of EVs might prevent data from being misinterpreted and allow results to be generalized [23].

The platelet count: spleen diameter ratio, proposed by Giannini et al. [23], appears to be one of the best noninvasive predictors of EVs that have emerged [25]. There have been attempts to associate various biochemical markers to assess the presence of esophageal varices. Levels of Aspartate Transaminase (AST) and Alanine Transaminase (ALT) being the more commonly used. With progression of chronic liver disease (CLD), there is derangement of liver enzyme values, with a rise in AST and ALT, with AST>ALT.

If non-invasive tests can predict the presence of esophageal varices, then the use of endoscopy can be limited to patients identified to be at risk of varices. With this in mind, in this study we used the platelet count/spleen diameter ratio and AST/ALT as a parameter for detecting EV.

All the patients who have undergone EVL should be periodically monitored with Hepatic Venous Pressure Gradient (HVPG). But in our resource limited set up HVPG monitoring which is an invasive procedure is not feasible. So, this study aims to find out whether the platelet count/spleen...
diameter and AST/ALT ratio can be used as a non-invasive parameter to assess esophageal variceal grade and further to look whether it can predict the need for EVL or the patient has high risk of re-bleeding.

Aim of the study to identify clinical, biochemical and radiological parameters which might non-invasively predict the presence of esophageal varices and risk of bleeding in patients with liver cirrhosis.

RELEVANCE
Esophageal variceal bleed is one of the major complication in liver cirrhosis increasing its morbidity and mortality. Esophageal endoscopy is mandatory for all cirrhotic patients both for therapeutic and prophylactic purpose. It is an invasive method, requiring expert hands and not cost effective. This study is an attempt to identify the clinical, biochemical, and ultrasonographic parameters associated with the presence of Esophageal Varices, mainly Platelet count/Spleen diameter ratio and AST/ALT ratio, which is cost effective and simple.

MATERIALS AND METHODS
This study is a Diagnostic test evaluation of patients having cirrhosis with portal hypertension. Patients are selected according to inclusion & exclusion criteria who are admitted in Medicine and Gastroenterology wards. The diagnosis of cirrhosis is by clinical history, physical examination (jaundice, signs of CLD), laboratory investigations (LFT abnormalities), imaging with USG (nodular liver and coarse echotexture). Liver biopsy is not necessary. The diagnosis of portal hypertension is by ascites, splenomegaly, USG abdomen showing collaterals around gastrointestinal junction & splenic hilum, splenomegaly, dilated portal vein >12mm, dilated splenic vein >10mm and demonstration of esophageal varices by Esophageal endoscopy. The classification system is given below

GRADE ENDOSCOPIC APPEARANCE
0 Absent
1 Small straight varices not disappearing on insufflation
2 Medium varices occupying less than one third of the lumen
3 Large varices occupying more than one third of the lumen

Liver function tests were done using Transasia XL300 Clinical Chemistry analyzer. Bilirubin was measured by the Diaz reaction. AST and ALT by ultra-violet kinetic method, ALP by PNPP kinetic method and Total Protein and Serum Albumin by Biuret and BCG methods respectively. All these investigations are done free of cost in this institution. Platelet count/spleen diameter ratio is calculated by dividing the platelet number/mm3 by the maximum spleen bipolar diameter in millimeter as estimated by abdominal ultrasound. AST/ALT ratio is also calculated. With further statistical analysis the usefulness of these ratios as predictive score for Esophageal varices will be estimated.

The study design is a diagnostic test evaluation. A detailed history was taken, physical examination performed and baseline investigations noted using a structured proforma. Laboratory investigations
as done routinely during the evaluation of the patient were noted.
The data were analyzed using appropriate statistical methods to
determine the presence of any correlation of the Platelet count with Spleen
size in the various etiological groups.

**Study design:** Diagnostic test evaluation

**Study Period:** 1/11/2015 to 31/10/2016

**Sample size:** 140 cases.

**Inclusion Criteria**
All diagnosed cases of cirrhosis with portal hypertension admitted in medical and
gastroenterology wards during the study period.
The etiologies of cirrhosis includes alcoholic cirrhosis, HBV, HCV, Others (Wilson’s disease,
hemochromatosis, Alpha1 antitrypsin deficiency, Autoimmune hepatitis, and Non-alcoholic
steatohepatitis, Biliary cirrhosis, Cardiac cirrhosis & Cryptogenic cirrhosis.)

**Exclusion Criteria:**
1. All patients with other quantitative platelet abnormalities & disorders like ITP,
   Leptospirosis, Dengue fever, Hematological malignancies.
2. Other causes of splenomegaly - myelofibrosis, lymphoma, IMN, malaria and EHPVO.
3. Patients <12 yrs 40
4. Patients suffering from acute liver failure
5. Non-cirrhotic portal hypertension
6. Hemodynamically compromised patients
7. Patients who had previously undergone sclerosis or band ligation of EV,
   transjugular intrahepatic portosystemic stent shunt
8. Patients taking drugs for primary prophylaxis of variceal bleeding
9. Those who do not consent to the study.

**RESULTS**
Total 140 patients were included in the study. The following were the observations.
Fig no. 4: Presence of upper GI bleed

Fig No.5: Comorbidities

Fig No.6: Etiology of Chronic liver disease

Fig No.7: Prevalence of Portal hypertensive gastropathy (PHG)

Fig No.8: Variceal grading

Fig no. 9: Receiver operating characteristics curve showing PLC/ BPD ratio

ROC curve showing PLC/ BPD ratio with area under curve 0.908 cut off value 919 with sensitivity 74 % specificity 88 %
DISCUSSION
In this study conducted, a total of 140 patients were included those who have satisfied the inclusion criteria.

AGE AND GENDER DISTRIBUTION
These patients were grouped into different age groups. Of these 37.9% of the patients were in the 40-49 age group and 32.1% of patients were in the 50-59 age group. Majority of study population was between 40-59 years of age group (70%). 90% of patients were males and the rest females constituting only a minor fraction.

PRESENTING COMPLAINT
The major presenting complaint was upper gastrointestinal bleed (78.6%) with or without other complaints. Remaining 22.4% patients presented with abdominal distention, abdominal pain, hepatic encephalopathy, jaundice. Upper gastrointestinal bleed was the only complaint in about 59.3%. In a population based study endoscopy was performed in 241 patients who presented with upper GI bleed and diagnoses were: peptic ulcer 61.6%, mucosal erosive disease 14.3%, varices 6.2%, miscellaneous 9.7%, and unknown 8.1%.

DISTRIBUTION OF COMORBIDITIES
There were no comorbidities in 103 individuals, 25 had diabetes mellitus and 12 had hypertension.

ETIOLOGY
On analyzing the etiology the major etiological factor was alcohol which was present in 80% of the patients. 12.1% had HBV infection and 6.4% had HCV infection as their causative factor for their chronic liver disease. Remaining 1.4% constituted other cause like NASH and Cryptogenic liver cirrhosis. In developed countries major cause for cirrhosis is viral hepatitis and alcohol is only a second cause. The cause of cirrhosis in female in the study is mainly viral etiology.
DISTRIBUTION OF VARICEAL GRADE
In the present study 37.1% had Grade 2 varices, 33.6% had Grade 1 varices and 16.4% had Grade 3 varices. 12.9 % had no varices. 87.1 % had portal hypertensive gastropathy.

STATISTICAL ANALYSIS
The ratios namely platelet count/bipolar diameter of spleen (PLC/BPD), AST/ALT ratio were analysed using receiver operating characteristics (ROC) curves and its statistical significance was calculated using test like Mann-Whitney U and p value was calculated.

RESULT
In this study ROC curve showing PLC/ BPD ratio with area under curve 0.908 which denotes a good test and cut off value 919 with sensitivity 74 %, specificity 88% which is statistically significant with a p value < .001. According to Khaled El-Molaet al, the PLC/BPD ratio in patients with EVs was significantly lower than in patients without EVs. In an analysis of ROC curves test had a good diagnostic accuracy [AUC= 0.99] the best cutoff value was 976.0 with sensitivity of 99.3% and specificity of 97.4%. ROC curve showing AST/ALT ratio was also plotted in the present study with area under curve 0.794 cut off value 1.30 with sensitivity 74% specificity 82 % which is statistically significant with a p value < .001. In a retrospective study, significantly higher AST/ALT ratios were seen in patients with varices compared to those without (ratio: 1.8 versus 1.0, P < 0.0001). A study by Castéra L et al, using a different cut-off of ≥1.0 demonstrated a sensitivity of 68%, specificity of 89%, PPV 77%, and NPV 83%, with an AUROC 0.83 (0.72–0.94) for predicting the presence of oesophagealvarices. For the prediction of large oesophagealvarices, this gave a sensitivity 68%, specificity 77%, PPV 41%, and NPV 92%, and AUROC 0.79 (0.64–0.94).

SUMMARY AND CONCLUSION
This is a Descriptive study in order to find out the diagnostic efficacy of platelet count/spleen diameter ratio and AST/ALT as a non-invasive marker for esophageal varices in liver cirrhosis. 140 patients with features of chronic liver disease were taken up for the study. Clinical, biochemical, radiological assessment and endoscopy was done and appropriate analysis was done. Results are as follows:
- Majority of patients with cirrhosis and portal hypertension were males (90%) and the age group 40-59(69%).
- The most common presenting complaint was upper gastrointestinal bleed present in 78.6% of the patients.
- Most common etiology for cirrhosis is chronic alcoholism.
- 87.1% had portal hypertensive gastropathy at the time of presentation.
- 37.1% had Grade 2, 33.6% had Grade 1, 16.4% had Grade 3 and 12.9 % had absentvarices on endoscopy.
- PLC/ BPD ratio have sensitivity 74 % and specificity 88% which is statistically significant with a p value < .001. This ratio has a cut off value 919 with area under ROC curve 0.908 which denotes a good test.
- AST/ALT ratio have sensitivity 74% specificity 82 % which is statistically significant with a p value < .001 and the ratio have a cut off value 1.30 with area under ROC curve 0.794.

From this study I conclude that two non-endoscopic parameters: platelet count/splenic diameter ratio and AST/ALT ratio may be used to predict the presence of esophageal varices and use as surrogate markers for the presence of esophageal varices where endoscopic facilities not available. However endoscopy may still be required for diagnosing the esophageal and gastric varices and for therapeutic interventions. As such
these patients can be put on prophylactic treatment to prevent variceal bleeding.

**LIMITATIONS**

1. As this study has small sample size the observations cannot be generalized to the general population.
2. Larger studies should be carried out to confirm the findings of this study.

**REFERENCE**

1. Schiedermaier P. Splanchnic hemodynamics: cirrhotic versus non-cirrhotic portal hypertension. J Gastroenterol Hepatol 2004;19(s7):S150-S4.
2. Hong WD, Zhu QH, Huang ZM, Chen XR, Jiang ZC, Xu SH, et. Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study. BMC Gastroenterol. 2009;9:11.
3. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 2002;122(6):1620-30.
4. Garceau AJ, Chalmers TC. The Boston Inter-Hospital Liver Group. The natural history of cirrhosis: I. Survival with oesophageal varices NEJM1963;268:469–73.
5. Graham D, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800–9.
6. Rigo GP, Merighi A, Chalen JN, et al. A prospective study of the ability of three endoscopic classifications to predict hemorrhage from esophageal varices. Gastrointest Endosc 1992;38:425–9.
7. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 2002;122:1620–30.
8. Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998;28:868–80.
9. D’Amico G, Garcia-Tsao G, Calés P, et al. Diagnosis of portal hypertension: how and when. In: De Franchis R, ed. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford: Blackwell Science 2001;36–63.
10. Calés P, Desmorat H, Vinel JP, et al. Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut 1990;31:1298–302.
11. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33(5):846-52.
12. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol.2005;43(1):167-76.
13. Gorka W, al Mulla A, al Sebayel M, Altraif I, Gorka Qualitative hepatic venous Doppler sonography versus portal flowmetry in predicting the severity of esophageal varices in hepatitis C cirrhosis.AJR Am J Roentgenol. 1997;169(2):511-5.
14. Lavergne J, Molina E, Reddy KR, Jeffers L, Leon R, Nader AK, et al.Ascites predicts the presence of high grade varices by screening gastroscopy. Gastrointest Endosc. 1997;45(4):AB187.
15. Pilette C, Oberti F, Aube C, Rousselet MC, Bedossa P, GalloisY, et al. Noninvasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol. 1999;31(5):867-73.
16. Madhotra R, Mulcahy HE, Willner I, Reuben A. Prediction of esophageal varices
in patients with cirrhosis. J Clin Gastroenterol. 2002;34(1):81-5.

17. McCormick PA. The spleen, hypersplenism, and other relationships between the liver and spleen. In: Bircher J, Benhamou J-P, McIntyre N, eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1999:787–95.

18. Schepis F, Camma C, Niceforo D, Magnano A, Pallio S, Cinquegrani M, et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology. 2001;33(2):333-8.

19. Chalasani N, Imperiale TF, Ismail A, Sood G, Carey M, Wilcox CM, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol. 1999;94(11):3285-91.

20. Ng FH, Wong SY, Loo CK, Lam KM, Lai CW, Cheng SY. Prediction Of esophagogastric varices in patients with liver cirrhosis. J Gastroenterol Hepatol. 1999;14(8):785-90.

21. Zaman A, Hapke R, Flora K, Rosen HR, Benner K. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol. 1999;94(11):3292-6.

22. Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med. 2001;161(21):2564-70.

23. Giannini E, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut. 2003;52(8):1200-5.

24. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol. 2000;14(Suppl D):60D-6D.

25. de Franchis R. Noninvasive diagnosis of esophageal varices: is it feasible? Am J Gastroenterol. 2006;101(11):2520-2.

ABBREVIATIONS

ALT Alanine Transaminase
AST Aspartate Transaminase
AUROC Area Under ROC
CLD Chronic Liver Disease
CTP Child-Turcotte-Pugh
cGMP cyclic Guanosine monophosphate
DM Diabetes Mellitus
eNOS Endothelial NO synthase
ET-1 Endothelin-1
FHVP Free Hepatic Vein pressure
GABA Gamma-aminobutyric acid
HE Hepatic Encephalopathy
HSC Hepatic Stellate Cell
HTN Hypertension
HVPG Hepatic Venous Pressure Gradient
NO Nitric Oxide
ROC Receiver operating characteristics
TGF-β Transforming Growth Factor-β
TIPS Transjugular Intrahepatic Portocaval Shunt
WHVP Wedged Hepatic Venous Pressure